+34 620 10 75 37info@nanbiosis.com

Nanbiosis

You are here : Home / 2016 (Page 9)

Pablo Laguna, Scientific Director of the Unit 27 of NANBIOSIS, presents in the Neocom Days the research lines of the group Biomedical Signal Interpretation & Computational Simulation (BSICoS) of CIBER-BBN and I3A of University of Zaragoza.

NEOCOM DAYS are organized by the Alumni Association of Telecommunications at the University of Zaragoza (AATUZ) in order to gather once a year companies, students and teachers to pool developments in the sector of new technologies in the field of Communications.

Nanbiosis U27_Biomedical Signal Interpretation & Computational Simulation (BSICoS)_Zaragoza
• Read More

Recently, the COST Action CA15126 "Between Atom and Cell: Integrating Molecular Biophysics Approaches for Biology and Healthcare (MOBIEU)" has been approved. In this action, the Nanomol Group, coordinator of Unit6 of NANBIOSIS, represented by Imma Ratera has been directly involved being part of the Management Committee.

Molecular-scale biophysics is a dynamic and ever-expanding interdisciplinary field that aims to study biological macromolecules and assemblies as a whole, at an intermediate level between atomic-resolution structural descriptions and cellular-level observations (“Between Atom and Cell”), with significant applications in biomedicine and drug discovery. The MOBIEU Action aims to seed a large-scale pan-European interdisciplinary synergistic clustering, allowing to ally and synergize the power of spectroscopic, hydrodynamic, real-time microfluidic, thermodynamic and single-molecule approaches.

This novel open network will create an optimal environment for the development of innovative integrative biophysical approaches, at the level of data acquisition, analysis and modelling, as well as for the design of unprecedented and ambitious combinations of methodologies, to decipher more efficiently crucial biological phenomena and to overcome significant biomedical challenges.

Nanbiosis U6_Nanomol Group_ARBRE Zaragoza meeting - feb 2016
• Read More

On March 2, 2016 Esther Pueyo, Tenured Professor at the University of Zaragoza and member of the research group BSICoS of CIBER-BBN, presented the research lines of this group, that coordinates Unit 27 of NANBIOSIS, and described the ERC MODELAGE project, which was awarded with a 'Starting Grant' of the European Union funded with 1.5 million euros.

The project progresses in the characterization of human heart aging and the prevention of cardiac arrhythmias. Juan Pablo Martínez, coordinator of the BSICoS group, introduced and moderated the talk, which is incardinated in the series of seminars “Ateneo de la Escuela de Ingeniería y Arquitectura”, where ideas on science, technology, scientific thinking, social and human sciences, etc, are presented and discussed.

Current technology allows addressing multi-factorial and multi-scale research of cardiac electrophysiological behavior to improve arrhythmic risk stratification in aged hearts, both on a population basis but also on an individual basis. Esther Pueyo presented the methodologies proposed in the MODELAGE project for this purpose, which integrate in silico modeling with in vitro cell and tissue analysis and in vivo assessment of electrocardiographic recordings. All these investigations will be made possible thanks to the computational capabilities of Unit 27 High Performance Computing of NANBIOSIS.

Nanbiosis_U27-Esther Pueyo presents- Engineering at the service of health-study of human heart aging
• Read More

José Luis Pedraz, Scientific Director of the Unit 10: Drug Formulation of NANBIOSIS explained DRIVE European project in the third edition of Diabetes Experience Day, diabetic patients meeting that gathered 1500 people in Madrid. The DRIVE project, in which participate fourteen partners from seven European countries, among which is the CIBER-BBN, develops biomaterials and new surgical devices to improve transplantation and survival of insulin-producing pancreatic islet for the treatment diabetes.

 

The DRIVE project, in which participate fourteen partners from seven European countries, among which is the CIBER-BBN, develops biomaterials and new surgical devices to improve transplantation and survival of insulin-producing pancreatic islet for the treatment diabetes.

NANBIOSIS participation in the project focuses on the evaluation of the biocompatibility of new biomaterials with insulin-producing cells. These new biomaterials provided by Contipro will be compared with the biomaterials most frequently used to encapsulate cells such as alginate derivatives, a product obtained from seaweed.

At the same time, the research group coordinating Unit 10 of NANBIOSIS work in differentiating IPC insulin producing cells as an alternative to pancreatic islets for use in bioartificial organ source, with the aim of addressing the problems of availability of pancreatic islets for such therapies.

DRIVE European project 3rd edition of  Diabetes Experience Day.

Nanbiosis_Unit8-Drive Project-Improving transplant pancreatic cells_Dr. Jose Luis Pedraz
• Read More

The researcher Rosa Villa, Director of the Unit 8 of NANBIOSIS has developed this technology, in collaboration with other groups, within the framework of the project Graphene Flagship, the EU's biggest ever research initiative, in which CIBER-BBN participates.

These devices, that can detect the electrical activity of the brain, are currently being tested in animals by measuring their brain activity using  Graphene transitors and could have therapeutic applications, as well as allowing the design of new brain-machine interfaces.

Nanbiosis_Unit8-Graphene sensors presented in Mobile World Congress Barcelona 2016
• Read More

NANBIOSIS positions its research services before the European Innovation Ecosystem, participating in Transfers 2016 V European Forum for Science, Technology and Innovation, held in Málaga on 10 and 11 February 2016.

NANBIOSIS Coordinator, Jesús Izco, participated in the Round Table: “Promoting Innovation in ICTS” to explain the experience of NANBIOSIS. He spoke of the establishment of the ICTS, its portfolio of services and dissemination plan as means to achieve their maximum objective of innovation and transfer of technology developed through the Platform.

The forum brought together more than 2000 people, 120 speakers, 23 countries, 500 companies and institutions, 190 research groups, 40 universities and 37 technological platforms with more than 1,900 technological projects and represents an excellent opportunity for:

  • Transfer scientific knowledge and technological research lines
  • Introduce innovative products and services
  • Know the technological needs of the Public Administration
  • Establish B2B contacts
NANBIOSIS participated in ¡Promoting Innovation in ICTS - Málaga Spain Feb-2016
• Read More

NANBIOSIS participant of Retos–Colaboración 2016.

Due to the recent publication of the call Retos–Colaboración 2016, of the State Program of I + D + i, the Technology Platforms in the field of Health, in collaboration with the MINECO organized on February, 4th 2016, an Info Day in order to:

  • To encourage the participation of companies and research centers
  • To generate R & D proposals for the formation of consortia
  • To hold bilateral meetings to review proposals

The event included an informative part on the details of the call and a block of proposals and success stories. NANBIOSIS Coordinator, Jesús Izco, presented NANBIOSIS as an entity supporting R & D in collaboration, explaining how the Platform was developed to become part of the National Map of ICTS (Singular Scientific and Technical Infrastructures) and its range of services for the development of R + D + I.

The NANBIOSIS infrastructure is mainly engaged in research in the health field but from a more transversal and technological point of view than other research centres, with a relevant specialization in biomaterials and tissue engineering, bioengineering and nanomedicine and molecular diagnostics view. That more technological and finalist positioning in the health field, together with the excellence of researchers who coordinate the several units that make up the platform, situates NANBIOSIS as a benchmark for research projects and transfer.

NANBIOSIS participated in the conference organized by the Technology Platforms
• Read More

Stem cells for improving the biocompatibility of surgical meshes

JUMISC carried out an in vitro and in vivo study focused in the use of MSCs -coated surgical meshes to counteract the inflammatory response commonly observed after implantation.
Surgical meshes are medical devices traditionally used to solve hernias and prolapsed organs pathologies that may cause inflammation and foreign body reactions, causing pain and discomfort to the patient.
According to this, the JUMISC financed a R&D project to evaluate if MSCs may provide an anti-inflammatory environment after surgical implantation.
Magnetic resonance imaging, laparoscopic evaluation and histological studies were performed to evaluate safety aspects and its future clinical application as a bioactive material. The in vivo results demonstrated that they fulfill safety aspects and non-adverse effects.
The results have been published in Acta Biomaterialia, the second best journal in its area, whose authors are Rebeca Blázquez, Francisco Miguel Sánchez-Margallo, Verónica Álvarez, Alejandra Usón y Javier G. Casado. Moreover, according to the philosophy of JUMISC to promote the innovation and the quality of the patient life, from these results emerged an invention which is protected as a patent.
Finally, this project will continue and future experiments will be developed in a clinically relevant animal model for the extrapolation of the results to a clinical scenario.

mallamalla 2
Images of the MSC-s coated surgical meshes obtained by microscopy

malla 1
• Read More